Welcome to our dedicated page for Aytu Biopharma news (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu Biopharma stock.
Aytu BioPharma, Inc. (AYTU) is a Nasdaq-listed pharmaceutical company focused on advancing medicines for complex central nervous system diseases, with an emphasis on major depressive disorder (MDD) and attention deficit-hyperactivity disorder (ADHD). Its news flow reflects this focus, highlighting commercial progress, clinical positioning and corporate developments around its prescription portfolio.
A central theme in Aytu’s recent news is EXXUA (gepirone) extended-release tablets, a novel oral selective serotonin 5HT1a receptor agonist indicated for the treatment of MDD in adults. Company announcements have covered the commercial availability of EXXUA in the United States, its status as the first and only 5HT1a agonist approved by the U.S. Food and Drug Administration for MDD, and integration of EXXUA distribution into Aytu’s RxConnect patient access platform.
Investors following AYTU news will also see updates on the company’s ADHD Portfolio and Pediatric Portfolio performance, including revenue trends and commentary from management in quarterly operational and financial results. Aytu’s press releases discuss net revenue by portfolio, gross profit, adjusted EBITDA and investments related to the EXXUA launch.
In addition, Aytu regularly announces participation in investor conferences, healthcare summits and dedicated Investor Day events. These items often feature presentations by senior management and key opinion leaders in psychiatry, focusing on EXXUA’s clinical profile, market opportunity and the company’s broader CNS strategy. For investors and observers, the AYTU news page provides a centralized view of product launches, patent developments, financing updates and ongoing investor outreach activities.
Aytu BioScience, a specialty pharmaceutical company, announced its presentation at the LD Micro Virtual Investor Conference on December 15, 2020, at 2:20 PM ET. This conference features a new format, allowing each company a 10-minute presentation followed by a 10-minute Q&A session with investors and analysts. Aytu's portfolio includes unique FDA-approved products addressing significant patient needs in primary care and pediatrics. For more details, visit the webcast.
Aytu BioScience (NASDAQ:AYTU) announced an underwriting agreement with H.C. Wainwright & Co. for a public offering of 1,666,667 shares at $6.00 per share. Expected gross proceeds are approximately $10 million, aimed at working capital and corporate purposes. Furthermore, the underwriter has a 30-day option to purchase an additional 250,000 shares. This offering follows the company's previously filed registration statement and is subject to customary closing conditions.
Aytu BioScience (NASDAQ:AYTU) will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference on November 18, 2020, at 1:45 PM ET / 6:45 PM GMT. The presentation will highlight the company's focus on novel pharmaceutical products, including FDA-approved treatments for low testosterone and sleep aids. A webcast of the presentation will be available online. Aytu's portfolio includes various prescription and consumer healthcare products aimed at significant patient needs, along with COVID-19 testing solutions.
Aytu BioScience (NASDAQ:AYTU) will announce its operational results for Q1 FY2021, ending September 30, 2020, on November 12, 2020, at 4:30 PM ET. The conference call will address the company’s recent achievements and future strategies. Aytu’s portfolio includes unique FDA-approved products like Natesto, ZolpiMist, and Tuzistra XR. Additionally, the company has a rapid COVID-19 testing solution and has licensed the Healight technology for respiratory infections. A live webcast will be available for 90 days on their website.
Aytu BioScience reported record fiscal Q4 2020 revenue of $14.9 million, an increase of 82% sequentially and 766% year-over-year, surpassing its entire fiscal 2019 revenue. The company achieved $6.9 million in Consumer Health and $7.9 million in Rx net revenue. Adjusted EBITDA loss was narrowed to ($1.7 million), down from ($3.7 million) in Q4 2019, with $48.3 million in cash on hand. CEO Josh Disbrow highlighted strong revenue performance and positive momentum moving into fiscal 2021, driven by the integration of Aytu and Innovus businesses and upcoming product launches.
Aytu BioScience (NASDAQ:AYTU) will announce its operational results for the fiscal fourth quarter and full year ending June 30, 2020, during a conference call on October 6, 2020, at 4:30 PM ET. Key products include FDA-approved testosterone nasal spray, sleep aid, and other pediatric formulations. The company also distributes COVID-19 rapid tests and is developing Healight technology for respiratory infections. The Form 10-K will be filed post-market on the same day, providing further insights into Aytu’s performance and strategy.
Aytu BioScience (NASDAQ:AYTU) announced the rescheduling of its fourth quarter and FY 2020 conference call, originally set for September 24, 2020, due to additional workload from the Innovus Merger and the Cerecor pediatric portfolio acquisition. The call will discuss record revenue for the fourth quarter and full fiscal year, alongside business progress updates. Aytu's product portfolio includes innovative prescription products targeting significant patient needs, including treatments for low testosterone and pediatric health issues.
Aytu BioScience (NASDAQ: AYTU) will present operational results for the fiscal fourth quarter ending June 30, 2020, on September 24, 2020, at 4:30 p.m. ET. The call will highlight the company’s recent accomplishments and growth strategies. Interested parties can access the live webcast or the archived version on Aytu's website.
Aytu specializes in marketing novel pharmaceutical products, including the only FDA-approved nasal testosterone solution and an oral spray sleep aid. The company also distributes COVID-19 diagnostic tests and is developing a medical device platform for respiratory infections.
Aytu BioScience (NASDAQ:AYTU) has signed a global distribution agreement for the Pinnacle CovID RAD Rapid Antigen Detection Test, designed to deliver COVID-19 results in just fifteen minutes without laboratory equipment. The test, demonstrating 100% specificity and 84.3% sensitivity, is set to scale U.S. manufacturing capacity to 25 million tests per month. This partnership aims to enhance COVID-19 testing efficiency and response times, addressing significant testing bottlenecks as economies begin to reopen.
Aytu BioScience (NASDAQ:AYTU) has partnered with Apollo Med Innovations and Olympus Health and Performance to launch a nationwide mobile COVID-19 testing initiative. This collaboration aims to provide on-demand, compliant COVID-19 testing for companies, utilizing Aytu’s licensed IgG/IgM antibody tests. Apollo will employ sterilization technologies to ensure a safe testing environment. The initiative seeks to address the return-to-work challenge faced by businesses. Company executives highlighted the importance of providing a safe testing solution for employees and customers.